Acted as legal counsel to Hypertec Cloud Inc. in connection with the acquisition of the 5C Data Centers group of companies for USD $750,000,000

Acted on behalf of Capital régional et coopératif Desjardins and KF Matheson Holdings Corp., in their capacity as co-lead investors, in connection with a syndicated USD $ 25,000,000 investment in convertible Class A-2 Preferred Shares of Puzzle Medical Devices Inc

Acted on behalf of Epitopea, a transatlantic cancer immunotherapeutics company, in the negotiation and entering into of a license and research collaboration agreement with Merck & Co., Inc., to identify CryptigenTM tumor-specific antigens. Under the terms of the agreement, Merck has an exclusive option to develop and commercialize therapeutics derived from the collaboration

Acted on behalf the shareholders of Groupe ABS Inc. and its subsidiaries, a Quebec-based consulting engineering firm offering services in materials monitoring and engineering, metallurgy, geotechnics, environment, geophysics, building science and rock mechanics, in the sale of the majority of their shares to Groupe Ginger, a French company specializing in engineering.

Acted on behalf of Corbec Group in connection with the formation of a joint venture with Fabrimet Group for the acquisition of the shares of Galvanisation Quebec Inc. and the construction and operation of a hot dip galvanizing plant in Quebec

Acted on behalf of Epitopea Inc., a Canadian corporation, and Epitopea Limited, a U.K. corporation, in connection with the USD$31M (£24M) cross-border, pre-Series-A preferred share extension financing round of these companies, with an exchangeable share structure, led by a syndicate of international investors including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital (CIC), Fonds de solidarité des travailleurs et des travailleuses du Québec (FTQ), Investissement Québec, adMare BioInnovations (NEOMED Institute) and IRICoR. These companies are transatlantic biopharmaceutical company specializing in the development of off-the-shelf RNA-based cancer immunotherapeutics

Acted on nehalf of AGT Robotique Inc. and its shareholders in connection with the sale of the shares of AGT Robotique Inc. and its affiliates to a subsidiary of Gauge Capital LLC under a cross-border exchangeable share structure

Acted on behalf of KSH Solutions Inc., a Montreal-based consulting, engineering, and EPC/EPCM project delivery services company with extensive experience in capital intensive industries such as pulp & paper, chemicals and biorefining, as well as in, energy, water and environment sectors, in connection with the sale of its shares to AFRY Group Finland OY, a Swedish public company that provides engineering, design, digital and advisory services.

Acted on behalf of CTI Life Sciences Fund III L.P., 3B Future Health Fund and Panacea Venture Health Care Fund II, L.P., as lead investors, in connection with (a) the €39M cross-border, multi-tranche, Series A preferred share financing round of Domain Therapeutics S.A., a Paris-based biopharmaceutical company specializing in the research and development of innovative immuno-oncology drugs, and (b) the creation and financing of a Canadian operating subsidiary.

Acted on behalf of Baylis Medical Company Inc. and its shareholders in connection with the sale of the company’s cardiology activities to Boston Scientific Corporation for USD$1.75 billion and carve-out of its DMS business.

Acted on behalf of DMDConnects Services Inc. in the sale of its direct and indirect interests in, and assets used in connection with the operation of, DMD Marketing Corp., a healthcare identity provider dedicated to connecting marketers to key healthcare audiences, to IQVIA Inc. (NYSE:IQVIA).

Acted on behalf of Hypertec, a global provider of end-to-end technologies, in connection with (a) the sale of a major industrial commercial complex in Montréal, Québec to Equinix Canada Ltd., (b) the sale of its data center and colocation services operations to Vantage Data Centers, one of the world's leading hyperscale data center providers for a combination of an upfront price and complex earnout arrangement, (c) the acquisition of cloud.ca Inc., and (d) the acquisition of control of Hypertec and venture capital financing by F.I.T. Ventures.

Acted on behalf of Groupe Nexio Inc. in connection with its acquisition by NovaCap.

Acted on behalf of Corbec Group in connection with the acquisition of a hot dip galvanizing plant in Nova Scotia.

Acted on behalf of Canassurance Financial Corporation, a not-for-profit health insurance provider operating in Ontario and Quebec, in connection with (a) the sale of its underwriting, marketing and administration of individual life, long-term disability, long-term care, and critical illness insurance business to Blue Cross Life Insurance Company of Canada, and (b) the sale of all of the shares of SecuriGlobe Inc., a wholly-owned subsidiary of Navacord Corp.

Acted on behalf of HIM Holdings LP and its related funds in connection with the sale of the student residence complex situated at 420 Sherbrooke Street West, Montreal, Quebec to ECV Montreal LP.

Acted on behalf of Merck Canada Inc. in connection with the Canadian aspects of the spin-off of Merck & Co.’s women’s health, legacy products and biosimilars business, which created the new company named Organon & Co. and various subsidiaries in Canada and throughout the world.

Acted on behalf of Corbec Group in connection with the conclusion of a joint venture for the construction and operation of a hot dip galvanizing plant in the Toronto Metropolitan.

Acted on behalf of Biodextris Inc., as co-licensor with The Brigham and Women’s Hospital, Inc., in the negotiation of a global development and commercialization agreement with I-Mab Biopharma US Limited and Jiangsu Nhwa Pharmaceutical Co., Ltd. in relation to innovative products and processes for the treatment of neurological diseases in humans.

Acted on behalf of Baylis Medical Company in its venture arm preferred share investment in Epineuron Technologies Inc. and in its subsequent common share financing and acquisition of control of Epineuron, a bioelectronic medical company that provides therapy to support patients with peripheral nerve regeneration.

Acted on behalf of Klox Technologies Inc. in connection with the establishment of a joint venture company in Ireland with LEO Pharma A/S.

Acted on behalf of sanofi-aventis Canada Inc. in connection with a swap of assets with Johnson & Johnson.

Acted on behalf of TI Life Sciences Fund as lead investor in connection with (a) CTI’s participation in the €130M Series C equity financing of Amolyt Pharma that was lead by Sofinnova Partners and co-lead by Intermediate Capital Group, (b) CTI’s participation with BVF Partners, Omega Funds, Cowen Healthcare Investments et al., in the $138M transaction financing of enGene Inc., a clinical-stage biotechnology company listed on NASDAQ, developing non-viral gene therapies based on its proprietary dually derivatized chitosan platform that are re-dosable, manufacturable at scale and designed to be seamlessly integrated into community clinical practices across the globe, (c) the formation and Series A multi-tranche financing with adMare BioInnovations and Domain Therapeutics of Find Therapeutics Inc. and its acquisition of the assets of Peptimimesis S.A., (d) the US$6M Series A-3 preferred share seed financing in Phenomic AI Inc., a Toronto-based company which leverages a computer vision and high content screening platform to develop therapeutic antibodies against cancer and fibrosis, (e) three separate multi-tranche private placements of $3.2M, $2.5M and $2M principal amount secured convertible debentures of Zymeworks Inc. of Vancouver, the conversion of such debentures into equity, the subsequent rounds of preferred share financings and the initial public offering of Zymeworks Inc., (f) the $10M Series A multi tranche financing of Xagenic Canada Inc. and in the subsequent $20M Series B and $15M Series B-1 multi-tranche financings and convertible debt financing of Xagenic Canada Inc. of Toronto, (g) the series C preferred share financing of Phemi Systems Corporation, (h) the $100M Series B preferred share financing of DalCor Pharmaceuticals Canada Inc. and DalCor Pharma UK Ltd., (i) the cross-border, tracking share financing of NeurAxon Inc., and (j) the US$9.5M series C multi-tranche financing of CellAegis Devices Inc., a Toronto based medical device company.

Acted on behalf of Skyfold Investments Ltd. and its shareholders in connection with the sale of the company to dormakaba for $109 million.

Acted on behalf of hydro-Québec Production in connection with the acquisition of a 60% interest in the hydroelectric facility located on the Manicouagan River in Quebec from Abitibi-Consolidated Company of Canada, a subsidiary of AbitibiBowater Inc. ($615M).

Acted on behalf of Enobia Pharma Corp in connection with the negotiation and execution of a Merger Agreement with Alexion Pharmaceuticals, Inc. whereby Enobia was acquired by Alexion for US$1.08B, and in connection with its previous $40.1M Series B financing, US$50M series C financing, US$45M Series C extension financing, US$40M common stock financing and US$20M secured debt financing - Winner of LMG Life Sciences 2013 Award - Canadian Impact Deals of the Year.

Acted on behalf of Milgram & Company Ltd. and its shareholders in connection with the sale of the company to C.H. Robinson Worldwide, Inc. for a purchase price of approximately $62 million.

Acted on behalf of the owners of 3 senior residence facilities located in Moncton, New Brunswick in connection with the sale thereof to Moncton Retirement Limited Partnership, indirectly controlled by Hillcore Real Estate Investments Ltd.

Acted on behalf of Valeant Pharmaceuticals on its US$3.2B merger with Biovail, Canada’s largest publicly traded pharmaceutical company, and on its subsequent $1.5B, $1B and $650M cross-border private placements and on senior secured credit facilities. Also advised on Valeant’s acquisitions, through its Canadian subsidiary, of Dr. Renaud Inc and Renaud Skin Care Products Inc, worth $23M, and of Vital Science, Derma Glow and All Healthy Skin, worth $10.5M.

Acted as a canadian counsel to TerSera Therapeutics LLC in connection with (a) the purchase of the commercial rights to Zoladex® in the United States and Canada from AstraZeneca UK Limited for USD$250M plus certain milestone and royalty fees and (b) the concurrent first lien and second lien financing thereof.

Acted on behalf of Raymond Chabot Grant Thornton & Co. L.L.P. in connection with the sale of its real estate consultancy services business in the Province of Quebec to Jones Lang Lasalle Real Estate Services, Inc.

Barreau du Québec

LL.L.

LL.B.

B.Comm.

Canadian Bar Association

Quebec Bar Association

Association for Corporate Growth Toronto